WP6 - Clinical studies


The specific objectives are:

  1. Building on WPs 3-5, to define an optimal immunomonitoring strategy for testing potentially tolerogenic therapies.

  2. Building on data from WP2, to reach a consensus for the optimal and precise target population(s) for studies of potentially tolerogenic therapies in individuals at-risk for development of RA or in the earliest stages of RA.

  3. To explore trial strategies that may enable consecutive testing of a number of potentially tolerogenic therapies in the population(s) defined in objective 2.

  4. To determine which tolerogenic therapies to test in the population defined in objective 2.

  5. To design efficient but informative experimental medicine studies of interventions defined in objective 4, for patients defined in objective 2.


  • KI

  • DRFZ

  • MUW

  • UKER

  • UNEW (lead)

  • UGLA

  • LUMC

  • UQ

  • SE

  • UCB

  • GSK

  • BMS (lead)


  • Follow us on Twitter

Follow us on Twitter:

The RTCure project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement no 777357. This joint undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA.

The communication reflects the author's view; neither IMI nor the European Union or EFPIA  are responsible for any use that may be made of the information contained herein.